CCR2 Expression Promotes Diffuse Large B-Cell Lymphoma Survival and Invasion
Abstract Background CC chemokine receptor 2 (CCR2), has been regarded to involve in tumor growth, angiogenesis, epithelial mesenchymal transition, metastasis and immune escape etc. in recent years, but the role and mechanism in DLBCL has not been reported yet. Methods We examined the expression of CCR2 and assessed the relationship between the expression level of this receptor and the clinicopathological characteristics of DLBCL patients. Next, characterization of CCR2 expression in the development of DLBCL cell lines was explored by blocking CCR2 expression through a novel antagonist in vitro and in vivo. Results We showed that CCR2 expression was an independent prognostic marker that influenced DLBCL patients and predicted shorter overall survival (OS) and progression-free survival (PFS). The results showed that CCR2 antagonists inhibited the ability of DLBCL cells to proliferate, migrate and promoted apoptosis by activating the PI3K/Akt signaling pathway and the p38MARK signaling pathway. Furthermore, in vivo experiments, also confirmed that CCR2 antagonists inhibited the proliferation and metastasis of DLBCL neoplasms. Conclusion Our study demonstrates that CCR2 expression plays an important role in the development of DLBCL by stimulating cell proliferation, migration and anti-apoptosis. The inhibition of CCR2 may, therefore, be a potential target for anticancer therapy in DLBCL..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ResearchSquare.com - (2022) vom: 03. Apr. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hu, Quan-Quan [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.21203/rs.3.rs-1360177/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA035291230 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA035291230 | ||
| 003 | DE-627 | ||
| 005 | 20230429182531.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220222s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-1360177/v1 |2 doi | |
| 035 | |a (DE-627)XRA035291230 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-1360177/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Hu, Quan-Quan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CCR2 Expression Promotes Diffuse Large B-Cell Lymphoma Survival and Invasion |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background CC chemokine receptor 2 (CCR2), has been regarded to involve in tumor growth, angiogenesis, epithelial mesenchymal transition, metastasis and immune escape etc. in recent years, but the role and mechanism in DLBCL has not been reported yet. Methods We examined the expression of CCR2 and assessed the relationship between the expression level of this receptor and the clinicopathological characteristics of DLBCL patients. Next, characterization of CCR2 expression in the development of DLBCL cell lines was explored by blocking CCR2 expression through a novel antagonist in vitro and in vivo. Results We showed that CCR2 expression was an independent prognostic marker that influenced DLBCL patients and predicted shorter overall survival (OS) and progression-free survival (PFS). The results showed that CCR2 antagonists inhibited the ability of DLBCL cells to proliferate, migrate and promoted apoptosis by activating the PI3K/Akt signaling pathway and the p38MARK signaling pathway. Furthermore, in vivo experiments, also confirmed that CCR2 antagonists inhibited the proliferation and metastasis of DLBCL neoplasms. Conclusion Our study demonstrates that CCR2 expression plays an important role in the development of DLBCL by stimulating cell proliferation, migration and anti-apoptosis. The inhibition of CCR2 may, therefore, be a potential target for anticancer therapy in DLBCL. | ||
| 700 | 1 | |a Wen, Zhao-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Qi-Tang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhai, Zhi-Min |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yan-Li |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2022) vom: 03. Apr. |
| 773 | 1 | 8 | |g year:2022 |g day:03 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-1360177/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 03 |c 04 | ||
| 953 | |2 045F |a 570 | ||